While the previous two deaths occurred in patients treated with Elevidys, the most recent patient had received one of Sarepta Therapeutics\' investigational treatments.\n Following a tumultuous week for Sarepta Therapeutics, the biotech has confirmed that a third patient has died after receiving one of the company’s gene therapies. While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of Sarepta\'s investigational treatments.As

STOCKHOLM, July 18, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) and Radiology Oncology Systems, Inc. (ROS) are pleased to announce a strategic partnership, aiming at identifying and pursuing opportunities involving both emerging and existing technologies, with focus on the integration of refurbished linear accelerators with advanced software solutions. The collaboration has already resulted in several agreements. The purpose of the partnership is to jointly offer comprehensive solution

The FDA issued a complete response letter to Roche’s Columvi, saying the data that the company provided for the label expansion aren’t sufficient. Roche’s Genentech had been seeking approval for Columvi in combination with gemcitabine and oxaliplatin for patients with relapsed/refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant. It announced the rejection on Friday. An advisory committee convened in May largely voted against the label expansion, with

DEERFIELD, Ill.--(BUSINESS WIRE)--TerSera Therapeutics LLC, a biopharmaceutical company with a focus in oncology, rare disease, and non-opioid pain management, announced today that its collaborative research on intrathecal ziconotide (PRIALT®) prescribing patterns has been accepted for presentation at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN) taking place July 17-20, 2025, in Miami, Florida. The poster will be presented by the primary author, Tolga Suvar, M.D

GA, UNITED STATES, July 18, 2025 / EINPresswire.com / -- A deadly tick-borne illness, severe fever with thrombocytopenia syndrome ( SFTS ), continues to claim lives with no specific antiviral treatment. However, a breakthrough study reveals that lipoxygenase (LOX), an enzyme previously known for its role in inflammation, etc., can effectively halt the progression of SFTS virus (SFTSV) infection. By disrupting the viral envelope through lipid peroxidation, LOX prevents the virus from infecting ho

BETHLEHEM, Pa., July 18, 2025 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium Injections into the U.S. market, expanding its portfolio to include 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL). These launches expand B. Braun's portfolio to become the largest offering of Heparin Premixed bag

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in late Q3 2025 U.K. is the largest market outside the U.S. for adrenaline (epinephrine) auto-injector sales SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering

The National Ovarian Cancer Coalition & Foundation for Women’s Cancer fund research advancing early detection, equity & patient care. At NOCC, we believe that research is the foundation of hope for everyone impacted by ovarian cancer.” — Melissa Aucoin, CEO of the National Ovarian Cancer Coalition TX, UNITED STATES, July 18, 2025 / EINPresswire.com / -- The National Ovarian Cancer Coalition (NOCC) and the Foundation for Women’s Cancer proudly announces the recipients of the 2025 NOCC Research Aw

Rising biotech deals involving Chinese drugs, Takeda's positive OX2R readouts, and LaNova's acquisition by Sino Biopharm made our news this week. Biotech deals involving assets developed in China are surging, a Jefferies report shows. Takeda is preparing its narcolepsy candidate oveporexton for an FDA filing after two positive phase 3 readouts. Merck & Co.'s PD-1xVEGF partner is being acquired. And more.1. China biotechs ‘reshaping’ US biopharma as outlicensing deals rise 11%: Jeffe

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices for enteral feeding, pain management and urological conditions, today announced it has entered into a definitive agreement with an institutional investor for the purchase and sale of 8,889 shares of Series H Convertible Preferred Stock (the “Preferred Stock”) with a total stated value of $8,888,889. The Preferred Stock is convertible